4:06 PM ET
8-K
Nasdaq/NYSE Compliance Notice
Akebia Therapeutics Nasdaq/NYSE Compliance Notice
Akebia Therapeutics received a deficiency notice from Nasdaq because its common stock closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until April 19, 2027, to regain compliance, which requires the stock to close at $1.00 or higher for at least 10 consecutive business days. Akebia is evaluating options to cure the deficiency, including a potential reverse stock split.
- Counterparty
- Nasdaq
- Term
- 180 days